For the period of 28 February 2021 to 06 March 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 28 February – 06 March 2022
Preliminary Recommendation for the Inclusion of Rituximab 1400 mg/11.7 mL Solution for Subcutaneous (SC) Injection for the Treatment of Non-Hodgkin’s Lymphoma
Document link: Evidence Summary on Subcutaneous Rituximab for the Treatment of Non-Hodgkin’s Lymphoma (Proponents may submit appeals to hta@doh.gov.ph until 18 March 2022.) Document Preview:
Evidence brief for 21 February – 27 February 2022
For the period of 21 February 2021 to 27 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 21 February – 27 February 2022
Evidence brief for 14 February – 20 February 2022
For the period of 14 February 2021 to 20 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 14 February – 20 February 2022
Evidence brief for 07 February – 13 February 2022
For the period of 07 February 2021 to 13 February 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 07 February – 13 February 2022